NPM-ALK and the junb transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma

International Journal of Clinical and Experimental Pathology

Volumn 4, Issue 2, 2011, Pages 124-133

  Pearson, Joel D ^a   Lee, Jason K H ^a   Bacani, Julinor T C ^a   Lai, Raymond ^a,b   Ingham, Robert J ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

Alk+ alcl; Granzyme B; Junb; Npm alk; Perforin

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; GRANZYME; MESSENGER RNA; ONCOPROTEIN; P80(NPM ALK) PROTEIN; P80(NPM-ALK) PROTEIN; PORE FORMING CYTOTOXIC PROTEIN; PRF1 PROTEIN, HUMAN; PROTEIN C JUN; PROTEIN TYROSINE KINASE;

ARTICLE; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; LARGE CELL LYMPHOMA; METABOLISM; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANZYMES; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; ONCOGENE PROTEINS, FUSION; PORE FORMING CYTOTOXIC PROTEINS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-JUN; RECEPTOR PROTEIN-TYROSINE KINASES; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 79958727941     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Delsol G FB, Muller-Hermelink H, Campo E, Jaffe E, Gascoyne R, Stein H and Kinney M. Anaplastic Large Cell Lymphoma (ALCL), ALKpositive In: Swerdlow S CE, Harris N, Jaffe E, Pileri S, Stein H, Thiele J and Vardiman J, editors. International Agency for Research on Cancer (IARC). Lyon; 2008. p. 312-316.
2. Foss HD, Anagnostopoulos I, Araujo I, Assaf C, Demel G, Kummer JA, Hummel M and Stein H. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood 1996; 88: 4005-4011.
3. d'Amore ES, Menin A, Bonoldi E, Bevilacqua P, Cazzavillan S, Donofrio V, Gambini C, Forni M, Gentile A, Magro G, Boldrini R, Pillon M, Rosolen A and Alaggio R. Anaplastic large cell lymphomas: a study of 75 pediatric patients. Pediatr Dev Pathol 2007; 10: 181-191.
4. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL and Look AT. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281-1284.
5. Chiarle R, Voena C, Ambrogio C, Piva R and Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008; 8: 11-23.
6. Amin HM and Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 2007; 110: 2259-2267.
7. Staber PB, Vesely P, Haq N, Ott RG, Funato K, Bambach I, Fuchs C, Schauer S, Linkesch W, Hrzenjak A, Dirks WG, Sexl V, Bergler H, Kadin ME, Sternberg DW, Kenner L and Hoefler G. The oncoprotein NPM-ALK of anaplastic largecell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood 2007; 110: 3374-3383.
8. Watanabe M, Sasaki M, Itoh K, Higashihara M, Umezawa K, Kadin ME, Abraham LJ, Watanabe T and Horie R. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. Cancer Res 2005; 65: 7628-7634.
9. Shaulian E and Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4: E131-136.
10. Shaulian E. AP-1-The Jun proteins: Oncogenes or tumor suppressors in disguise? Cell Signal 2010; 22: 894-899.
11. Mathas S, Hinz M, Anagnostopoulos I, Krappmann D, Lietz A, Jundt F, Bommert K, Mechta-Grigoriou F, Stein H, Dorken B and Scheidereit C. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 2002; 21: 4104-4113.
12. Rassidakis GZ, Thomaides A, Atwell C, Ford R, Jones D, Claret FX and Medeiros LJ. JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis. Mod Pathol 2005; 18: 1365-1370.
13. Szremska AP, Kenner L, Weisz E, Ott RG, Passegue E, Artwohl M, Freissmuth M, Stoxreiter R, Theussl HC, Parzer SB, Moriggl R, Wagner EF and Sexl V. JunB inhibits proliferation and transformation in B-lymphoid cells. Blood 2003; 102: 4159-4165.
14. Hsu FY, Johnston PB, Burke KA and Zhao Y. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosminanaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner. Cancer Res 2006; 66: 9002-9008.
15. Ingham RJ, Raaijmakers J, Lim CS, Mbamalu G, Gish G, Chen F, Matskova L, Ernberg I, Winberg G and Pawson T. The Epstein-Barr virus protein, latent membrane protein 2A, co-opts tyrosine kinases used by the T cell receptor. J Biol Chem 2005; 280: 34133-34142.
16. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
17. Glimcher LH, Townsend MJ, Sullivan BM and Lord GM. Recent developments in the transcriptional regulation of cytolytic effector cells. Nat Rev Immunol 2004; 4: 900-911.
18. Hanson RD, Grisolano JL and Ley TJ. Consensus AP-1 and CRE motifs upstream from the human cytotoxic serine protease B (CSP-B/CGL-1) gene synergize to activate transcription. Blood 1993; 82: 2749-2757.
19. Babichuk CK and Bleackley RC. Mutational analysis of the murine granzyme B gene promoter in primary T cells and a T cell clone. J Biol Chem 1997; 272: 18564-18571.
20. Dukers DF, ten Berge RL, Oudejans JJ, Pulford K, Hayes D, Misere JF, Ossenkoppele GJ, Jaspars LH, Willemze R and Meijer CJ. A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphomas. J Clin Pathol 1999; 52: 129-136.
21. Drakos E, Leventaki V, Schlette EJ, Jones D, Lin P, Medeiros LJ and Rassidakis GZ. c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders. Am J Surg Pathol 2007; 31: 447-453.
22. Leventaki V, Drakos E, Medeiros LJ, Lim MS, Elenitoba-Johnson KS, Claret FX and Rassidakis GZ. NPM-ALK oncogenic kinase promotes cellcycle progression through activation of JNK/ cJun signaling in anaplastic large-cell lymphoma. Blood 2007; 110: 1621-1630.
23. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G and Linsley PS. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003; 21: 635-637.
24. Hagn M, Schwesinger E, Ebel V, Sontheimer K, Maier J, Beyer T, Syrovets T, Laumonnier Y, Fabricius D, Simmet T and Jahrsdorfer B. Human B cells secrete granzyme B when recognizing viral antigens in the context of the acute phase cytokine IL-21. J Immunol 2009; 183: 1838-1845.
25. Jahrsdorfer B, Vollmer A, Blackwell SE, Maier J, Sontheimer K, Beyer T, Mandel B, Lunov O, Tron K, Nienhaus GU, Simmet T, Debatin KM, Weiner GJ and Fabricius D. Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion. Blood 2010; 115: 1156-1165.
26. Manyak CL, Norton GP, Lobe CG, Bleackley RC, Gershenfeld HK, Weissman IL, Kumar V, Sigal NH and Koo GC. IL-2 induces expression of serine protease enzymes and genes in natural killer and nonspecific T killer cells. J Immunol 1989; 142: 3707-3713.
27. DeBlaker-Hohe DF, Yamauchi A, Yu CR, Horvath-Arcidiacono JA and Bloom ET. IL-12 synergizes with IL-2 to induce lymphokine-activated cytotoxicity and perforin and granzyme gene expression in fresh human NK cells. Cell Immunol 1995; 165: 33-43.
28. Ambrogio C, Martinengo C, Voena C, Tondat F, Riera L, di Celle PF, Inghirami G and Chiarle R. NPM-ALK oncogenic tyrosine kinase controls Tcell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. Cancer Res 2009; 69: 8611-8619.
29. Han Y, Amin HM, Frantz C, Franko B, Lee J, Lin Q and Lai R. Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALKpositive anaplastic large cell lymphoma. Leukemia 2006; 20: 1602-1609.
30. D'Eliseo D, Pisu P, Romano C, Tubaro A, De Nunzio C, Morrone S, Santoni A, Stoppacciaro A and Velotti F. Granzyme B is expressed in urothelial carcinoma and promotes cancer cell invasion. Int J Cancer 2009; 21: 21.
31. Brugieres L, Deley MC, Pacquement H, Meguerian-Bedoyan Z, Terrier-Lacombe MJ, Robert A, Pondarre C, Leverger G, Devalck C, Rodary C, Delsol G and Hartmann O. CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood 1998; 92: 3591-3598.
32. Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, Verhoef G, Menestrina F, Todeschini G, Paulli M, Lazzarino M, Giardini R, Aiello A, Foss HD, Araujo I, Fizzotti M, Pelicci PG, Flenghi L, Martelli MF and Santucci A. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999; 93: 2697-2706.
33. Gascoyne RD, Aoun P, Wu D, Chhanabhai M, Skinnider BF, Greiner TC, Morris SW, Connors JM, Vose JM, Viswanatha DS, Coldman A and Weisenburger DD. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999; 93: 3913-3921.